Searched for: in-biosketch:true
person:husais06
The Case | Proximal muscle weakness, hypertension, and electrolyte abnormalities
Horn, Katharina W; Shah, Suraj S; Skoll, Devin; Carter, Danielle; Freeman, Natasha S; Husain, Syed A
PMID: 38519244
ISSN: 1523-1755
CID: 5868002
C3 Glomerulopathy Recurs Early after Kidney Transplantation in Serial Biopsies Performed within the First 2 Years after Transplantation
Tarragón, Blanca; Peleg, Yonatan; Jagannathan, Geetha; Sekulic, Miroslav; Chang, Jae-Hyung; Cohen, David J; Crew, Russell J; Dube, Geoffrey K; Fernandez, Hilda E; Husain, Syed Ali; Mohan, Sumit; Morris, Heather K; Appel, Gerald B; Jadav, Paresh; Santoriello, Dominick; Kudose, Satoru; Stokes, M Barry; Batal, Ibrahim; Bomback, Andrew S
BACKGROUND:C3 glomerulopathy (C3G), which encompasses C3GN and dense deposit disease (DDD), results from dysregulation of the alternative complement pathway. Data on disease recurrence after kidney transplantation are limited, and details on histologic features of recurrent C3G are scarce. We aimed to evaluate C3G recurrence in the allograft, with a focus on histologic presentation and progression. METHODS:We retrospectively analyzed 18 patients with native kidney failure attributed to C3G (12 C3GN and six DDD), who received a kidney transplant from January 2016 to January 2023. Demographic, genetic, clinical, and histologic data were studied. The NanoString 770 genes PanCancer Immune Profiling Panel was used for transcriptomic analysis. Disease recurrence was the primary outcome. RESULTS:During a median (interquartile range) follow-up period of 37 (18–56) months, C3G recurrence occurred in 16 (89%) patients (11 with C3GN and five with DDD) at a median (interquartile range) of 33 (13–141) days after transplantation. Over a third (38%) of recurrent cases were detected in protocol biopsies, and only 31% of patients presented with >300 mg/g of proteinuria. Recurrence in index biopsies was mainly established through a combination of immunofluorescence and electron microscopy findings, while it showed only subtle histologic alterations and no characteristic transcriptomic signals. Over time, histologic chronicity indices increased, but all the allografts were functioning at the end of follow-up. Patients with recurrence of C3GN and DDD showed overlapping immunofluorescence and electron microscopy findings and had similar recurrence rate and time to recurrence. CONCLUSIONS:Most of the patients with native kidney failure attributed to C3G developed disease recurrence very early after kidney transplantation, usually with minimal proteinuria, mild histologic alterations, and favorable short-term allograft survival. Immunofluorescence and electron microscopy played a crucial role in detecting early, subclinical recurrence of C3GN and DDD, which showed significant overlapping features.
PMCID:11321730
PMID: 39116277
ISSN: 1555-905x
CID: 5868052
Collapsing glomerulopathy is likely a major contributing factor for worse allograft survival in patients receiving kidney transplants from black donors
DiFranza, Lanny T; Daniel, Emily; Serban, Geo; Thomas, Steven M; Santoriello, Dominick; Ratner, Lloyd E; D'Agati, Vivette D; Vasilescu, Elena-Rodica; Husain, Syed Ali; Batal, Ibrahim
Although a few registry-based studies have shown associations between receiving kidney allografts from Black donors and shorter allograft survival, detailed, large, single-center studies accounting for common confounding factors are lacking. Furthermore, pathologic alterations underlying this potential disparity have not been systematically studied. We performed a retrospective clinical-pathological study of kidney transplant recipients who received kidney allografts from either Black (n = 407) or White (n = 1,494) donors at Columbia University Irving Medical Center from 2005 to 2018, with median follow-up of 4.5 years post-transplantation. Black donor race was independently associated with allograft failure (adjusted HR = 1.34, p = 0.02) and recipients of kidney allografts from Black donors had a higher incidence of collapsing glomerulopathy [7.4% vs. 1.9%, OR = 4.17, p < 0.001]. When causes of allograft failure were examined, only allograft failure following development of collapsing glomerulopathy was more frequent in recipients of allografts from Black donors [15% vs. 5%, OR = 3.16, p = 0.004]. Notably, when patients who developed collapsing glomerulopathy were excluded from analysis, receiving kidney allografts from Black donors was not independently associated with allograft failure (adjusted HR = 1.24, p = 0.10). These findings revealed that, compared with recipients of kidney allografts from White donors, recipients of kidneys from Black donors have modestly shorter allograft survival and a higher probability of developing collapsing glomerulopathy, which negatively impacts allograft outcome. Identification of collapsing glomerulopathy risk factors may help decrease this complication and improve allograft survival, which optimally may reduce racial disparities post-transplantation.
PMCID:10972956
PMID: 38549873
ISSN: 2296-858x
CID: 5868022
Use of Offer Bypass Filters under the Circular Kidney Allocation System [Letter]
Yu, Miko; King, Kristen L; Husain, S Ali; Schold, Jesse D; Mohan, Sumit
PMCID:11146644
PMID: 38568866
ISSN: 2641-7650
CID: 5868032
Radical Transparency to Improve Equity in the Kidney Allocation System
Husain, S Ali; Adler, Joel T; Mohan, Sumit
PMCID:10833597
PMID: 38010055
ISSN: 2641-7650
CID: 5867942
Developing a genetic testing panel for evaluation of morbidities in kidney transplant recipients
Ma, Becky M; Elefant, Naama; Tedesco, Martina; Bogyo, Kelsie; Vena, Natalie; Murthy, Sarath K; Bheda, Shiraz A; Yang, Sandy; Tomar, Nikita; Zhang, Jun Y; Husain, Syed Ali; Mohan, Sumit; Kiryluk, Krzysztof; Rasouly, Hila Milo; Gharavi, Ali G
Cardiovascular disease, infection, malignancy, and thromboembolism are major causes of morbidity and mortality in kidney transplant recipients (KTR). Prospectively identifying monogenic conditions associated with post-transplant complications may enable personalized management. Therefore, we developed a transplant morbidity panel (355 genes) associated with major post-transplant complications including cardiometabolic disorders, immunodeficiency, malignancy, and thrombophilia. This gene panel was then evaluated using exome sequencing data from 1590 KTR. Additionally, genes associated with monogenic kidney and genitourinary disorders along with American College of Medical Genetics (ACMG) secondary findings v3.2 were annotated. Altogether, diagnostic variants in 37 genes associated with Mendelian kidney and genitourinary disorders were detected in 9.9% (158/1590) of KTR; 25.9% (41/158) had not been clinically diagnosed. Moreover, the transplant morbidity gene panel detected diagnostic variants for 56 monogenic disorders in 9.1% KTRs (144/1590). Cardiovascular disease, malignancy, immunodeficiency, and thrombophilia variants were detected in 5.1% (81), 2.1% (34), 1.8% (29) and 0.2% (3) among 1590 KTRs, respectively. Concordant phenotypes were present in half of these cases. Reviewing implications for transplant care, these genetic findings would have allowed physicians to set specific risk factor targets in 6.3% (9/144), arrange intensive surveillance in 97.2% (140/144), utilize preventive measures in 13.2% (19/144), guide disease-specific therapy in 63.9% (92/144), initiate specialty referral in 90.3% (130/144) and alter immunosuppression in 56.9% (82/144). Thus, beyond diagnostic testing for kidney disorders, sequence annotation identified monogenic disorders associated with common post-transplant complications in 9.1% of KTR, with important clinical implications. Incorporating genetic diagnostics for transplant morbidities would enable personalized management in pre- and post-transplant care.
PMID: 38521406
ISSN: 1523-1755
CID: 5868012
Obesity is associated with a higher incidence of rejection in patients on belatacept: A pooled analysis from the BENEFIT/BENEFIT-EXT clinical trials
Lange, Nicholas W; King, Kristen; Husain, Syed Ali; Salerno, David M; Tsapepas, Demetra S; Hedvat, Jessica; Yu, Miko; Mohan, Sumit
Though belatacept is administered with a weight-based dosing schema, there has been higher clearance reported in obese patients. Therefore, we evaluated the association between body mass index (BMI) and transplant outcomes in kidney transplant recipients who were randomized to cyclosporine- or belatacept-based immunosuppression in the BENEFIT and BENEFIT-EXT randomized clinical trials. A total of 666 and 543 patients underwent randomization and transplantation in BENEFIT and BENEFIT-EXT, respectively, of which 1056 had complete data and were included in this analysis. Patients were grouped categorically according to BMI: <25, 25 to <30, and ≥30 kg/m2. BMI did influence both the incidence and severity of acute rejection. Obese patients with BMI >30 kg/m2 in the low intensity belatacept group experienced significantly more rejection at 12 months than did patients with BMI <25 kg/m2 or BMI 25 to <30 kg/m2. In both the moderate intensity belatacept and low intensity belatacept groups, obese patients with BMI >30 kg/m2 experienced significantly more severe acute rejection than did patients with BMI < 25 kg/m2 or BMI 25 to <30 kg/m2. These results suggest that obese kidney transplant recipients are at an increased risk for acute rejection when under belatacept-based immunosuppression when compared to nonobese patients.
PMCID:11930353
PMID: 38387620
ISSN: 1600-6143
CID: 5867992
Donor Estimated Glomerular Filtration Rate With or Without Body Surface Area Indexing and Kidney Transplant Graft Survival
Husain, Syed Ali; King, Kristen L; Mohan, Sumit
PMCID:11342767
PMID: 39184286
ISSN: 2590-0595
CID: 5868072
Allocation biopsies of deceased donor kidneys: a necessary tool to expand the donor pool
Husain, Syed Ali; Mohan, Sumit
PMCID:11956539
PMID: 39577988
ISSN: 1523-1755
CID: 5868082
Allocation and Utilization Patterns of Deceased Donor Kidneys for Preemptive Transplantation in the United States
King, Kristen L; Yu, Miko; Huml, Anne M; Schold, Jesse D; Husain, Syed Ali; Mohan, Sumit
PMID: 38284887
ISSN: 1533-3450
CID: 5867962